Effect of tusamitamab ravtansine on QTc interval in participants with metastatic solid tumors

Trial Identifier: TES16382
Sponsor: Sanofi
Start Date: October 2022
Primary Completion Date: August 2023
Study Completion Date: April 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
BELGIUM Edegem, BELGIUM, 2650
FRANCE DIJON, FRANCE, 21079
FRANCE MARSEILLE, FRANCE, 13385
SPAIN, Catalunya [Cataluña] Barcelona, Catalunya [Cataluña], SPAIN, 08023
SPAIN, Madrid, Comunidad de madrid, Madrid, Comunidad de, SPAIN, 28040
Turkey Ankara, Turkey, 06800
UNITED STATES, Texas Dallas, Texas, UNITED STATES, 75230